Search

Highlights from the SWG

The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.

Read more

Highlights from the SWG

Participation in EHA and ASH congresses. Planning of new common trials. Conduct of annual EMSCO meeting in Nice in October 2023.

Read more

Highlights from the SWG

Joint work with the International Society on Thrombosis and Haemostasis (ISTH), the European Association for Haemophilia and Allied Disorders (EAHAD), and the European Stroke Organisation (ESO) to produce guidance on antithrombotic treatment in patients with hemophilia.

Read more

Highlights of the SWG

SWG business meetingWe held a key strategic SWG business meeting on November 29, 2023, at the EHA offices in The Hague. During the meeting, we discussed the future plans and priorities of our SWG.

Read more

Highlights from the SWG

Project groupsPan-European Transfusion Research infrAstructure (PETRA) projectThe European Blood Alliance has provided funding for a health science data project entitled: ‘Towards a Pan-European Transfusion Research infrAstructure (PETRA).

Read more

Challenging the safety of conformity: Better poster design to disseminate scientific knowledge fast

“Congratulations – your abstract was accepted for the upcoming EHA congress”.

Read more

EHA24 is YOUR congress – here’s how you can make the most of it

Congress season is an exciting time for any field. It’s a time when experts come together to share the latest developments, and also an opportunity to see friends and colleagues who you haven’t seen in a while.

Read more

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

 

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more